MannKind to acquire V-Go insulin delivery device from Zealand Pharma

MannKind Corporation has agreed to acquire the V-Go wearable insulin delivery device from Zealand Pharma for $10 million plus sales-based milestones and inventory costs, expanding its diabetes portfolio.

“This acquisition strategically leverages our infrastructure in the diabetes space and positions MannKind's endocrine business for additional growth.”globenewswire.com

• 1 source
• globenewswire.comMannKind Corporation Announces Agreement to Acquire V-Go®MannKindMay 17, 2022

Summarized from public sources; check the original articles before acting on it.